Physician profile
Ritesh Gupta
NPI 1124100847
$10,919.08
in general payments reported to CMS, 2019-2025
47 companies · $2,163 in 2025
The $2,163 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,020 · 2020: $1,255 · 2021: $1,471 · 2022: $1,050 · 2023: $928 · 2024: $1,033 · 2025: $2,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,952 · Travel and Lodging: $1,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,952.46 |
| Travel and Lodging | $1,171.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,576.37 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,438.57 | 2019-2024 | Xarelto |
| Medtronic, INC. | $1,421.38 | 2021-2025 | Venaseal, Symplicity G3 |
| Boston Scientific Corporation | $1,418.84 | 2019-2024 | Watchman Flx, Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $762.11 | 2019-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $494.64 | 2019-2024 | |
| Amgen INC. | $470.47 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $448.96 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $305.31 | 2019-2025 | Jardiance |
| Abbott Laboratories | $196.32 | 2025 | Jot Dx, Mitraclip |
| Astellas Pharma US INC | $183.23 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $174.26 | 2020-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $173.75 | 2024-2025 | Verquvo |
| Amarin Pharma, INC. | $154.56 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $142.48 | 2019-2021 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $130.91 | 2022-2025 | Rybelsus, Ozempic |
| Atricure, INC. | $105.11 | 2023-2024 | |
| Lexicon Pharmaceuticals, INC. | $101.41 | 2024 | |
| Pfizer INC. | $94.95 | 2020-2024 | |
| Esperion Therapeutics, INC. | $90.51 | 2020-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $89.35 | 2024 | Arcalyst |
| Lundbeck LLC | $88.57 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $79.13 | 2019 | |
| Altathera Pharmaceuticals LLC | $70.14 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.09 | 2022-2025 | |
| Philips North America LLC | $64.57 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Gilead Sciences, INC. | $62.11 | 2019 | |
| Cardiva Medical, INC. | $61.28 | 2020-2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Daiichi Sankyo INC. | $53.21 | 2021-2023 | Injectafer |
| Scpharmaceuticals INC. | $51.52 | 2023-2025 | |
| Abiomed | $49.76 | 2019 | |
| Stryker Corporation | $35.02 | 2025 | Clottriever Bold Catheter |
| Inspire Medical Systems, INC. | $33.15 | 2024 | Inspire |
| Kiniksa Pharmaceuticals, LTD. | $27.04 | 2023 | Arcalyst |
| Echosens North America, INC. | $26.21 | 2023 | Fibroscan |
| Convatec INC. | $19.17 | 2021 | |
| Lantheus Medical Imaging, INC. | $18.77 | 2023 | Definity |
| Cardiofocus, INC. | $18.28 | 2019 | |
| Impulse Dynamics (USA) INC. | $17.90 | 2023 | Optimizer |
| Glaxosmithkline, LLC. | $16.20 | 2025 | Arexvy, Shingrix |
| Biosense Webster, INC. | $15.80 | 2021 | |
| Medtronic Vascular, INC. | $15.33 | 2020 | |
| Azurity Pharmaceuticals, INC. | $13.33 | 2023 | Edarbi |
| Vifor Pharma, INC. | $12.94 | 2019 | |
| Phathom Pharmaceuticals, INC. | $10.21 | 2025 | Voquezna |
| Cardiovascular Systems INC. | $9.74 | 2019 | |
| Cvrx, INC. | $9.12 | 2023 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ritesh Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.